Manufacturing Business EBITDA Multiple: 2026 Framework, 4 Drivers, and Real Ranges

The phrase ‘manufacturing business EBITDA multiple’ is asked far more often than it’s answered correctly. Search results return generic ranges (‘5-7x’) that ignore the layered framework sophisticated LMM PE buyers and strategic consolidators actually use to price deals. The real framework is industry baseline (set by sub-vertical and size band) plus four structural adjusters: size premium or discount, recurring contracted revenue percentage, customer concentration discount, and growth premium. Each adjuster moves you 0.25-1.5 turns inside or outside the baseline. Get the framework right and you produce a defensible multiple range; get it wrong and you anchor on a number that doesn’t survive QoE. For a deeper look, see our guide on ebitda multiple valuation.

This guide documents the actual EBITDA multiple framework used by manufacturing buyers in 2026. We’ll cover the baseline ranges by size band (sub-$2M, $2-5M, $5-10M, $10-25M, $25-50M, $50M+), the four adjusters with specific multiple impact ranges, sub-vertical-specific premiums (aerospace, medical device, plastics, electronics), how multiples compress for sub-$2M EBITDA businesses and expand for $5M+ EBITDA businesses, capital intensity normalization (the gap between reported and cash EBITDA), and how to triangulate from real data sources (GF Data DealStats, BVR DealStats, Pitchbook industrials, public 10-K disclosures from NASDAQ: HEICO, NYSE: Atkore, NYSE: APi Group, NYSE: Roper Technologies, TransDigm). For a deeper look, see our guide on ebitda multiple home services businesses.

The framework draws on direct work with 76+ active U.S. lower middle-market buyers — including 38 firms (50% of the network) with explicit manufacturing mandates. These buyers include manufacturing-focused PE platforms (Audax Industrial Services, Industrial Growth Partners, GenNx360 Capital Partners, Trive Capital, Mason Wells, Wynnchurch Capital, Argosy Capital, Sterling Group, Cortec Group, GTCR Industrials, Genstar Capital industrial investments, Carlyle Industrials, Bain Capital Industrials, Onex industrial investments), public strategic consolidators (NYSE: APi Group [APG], NYSE: Watsco [WSO], NYSE: Comfort Systems USA [FIX], NYSE: Roper Technologies [ROP], NASDAQ: HEICO [HEI], NYSE: Atkore [ATKR], TransDigm), family offices with industrial mandates, and the broader sub-LMM ecosystem of search funders, independent sponsors, and SBA buyers. We’re a buy-side partner. The buyers pay us when a deal closes — not you.

One realistic note before you start. EBITDA multiples are starting points for negotiation, not ending points. Real valuations live in a 25-35% range around any published baseline, and the actual multiple your business achieves depends on which buyers see the deal, what your books look like under QoE scrutiny, and how the deal structure resolves (asset versus stock, working capital peg, seller financing, earnout). Use the framework below to triangulate a defensible range — then validate with actual buyer feedback before treating the result as final.

“The right manufacturing EBITDA multiple is never a single number from a Pitchbook headline. It’s baseline (5-7x for general manufacturing at $5-10M EBITDA) plus four adjusters that compress or expand the multiple by a turn or two each. Get the four adjusters honest and you produce a defensible range. Skip them and you produce a number you cannot defend in front of a sophisticated LMM buyer at LOI — and the re-trade that follows kills more deals than any other single factor in manufacturing M&A.”

Key Takeaways

• Industry baseline + 4 factors framework: size premium/discount + recurring contracted revenue percentage + customer concentration discount + growth premium.
• 2026 baselines by size: sub-$2M EBITDA = 4-6x, $2-5M = 5-7x, $5-10M = 6-7.5x, $10-25M = 6.5-8.5x, $25-50M = 7-9.5x, $50M+ = 8-12x.
• Sub-vertical adjusters: aerospace AS9100/NADCAP +1-2 turns above baseline; medical device ISO 13485/FDA +2-4 turns; commodity CM at baseline; machine shop -1-2 turns or use SDE multiple.
• Sub-$2M EBITDA threshold: multiples compress because LMM PE platforms have $5-10M minimum equity check sizes that back into a $2-3M EBITDA floor. Below the floor, buyer pool collapses to search funders, independent sponsors, SBA buyers.
• $5M+ EBITDA threshold: multiples expand because full LMM PE competition emerges, mega-cap add-on programs activate, public strategic consolidators engage, and deal economics support higher diligence investment.
• Capital intensity normalization is mandatory: reported EBITDA − 3-year average maintenance capex (4-7% of revenue typical) = cash EBITDA, which sophisticated buyers anchor on within multiple ranges.

The 4-factor manufacturing EBITDA multiple framework

Sophisticated manufacturing M&A buyers price deals using a layered 4-factor framework: industry baseline plus size premium/discount plus recurring revenue percentage plus customer concentration discount plus growth premium. Each factor is independent, each moves the multiple by 0.25-1.5 turns, and the cumulative effect on a typical manufacturing deal is 1-3 turns of variance versus the baseline. This is the same framework Audax Industrial, Industrial Growth Partners, GenNx360 Capital Partners, Sterling Group, Wynnchurch Capital, and Trive Capital use during diligence to triangulate the multiple they’ll defend at investment committee.

Factor 1: industry baseline. Set by sub-vertical and size band. Sub-vertical determines the rough range (machine shop SDE multiples versus contract manufacturer EBITDA multiples versus aerospace versus medical device). Size band shifts you 1-2 turns inside the sub-vertical range. The baseline is the starting point that the four adjusters operate on. Establishing the right baseline matters: a $4M EBITDA precision machining business has a baseline of 6-8x, not the 5-7x of a general CM.

Factor 2: size premium / discount. Sub-$2M EBITDA: 0.5-1 turn discount versus baseline. $2-5M EBITDA: at-baseline. $5-10M EBITDA: 0.25-0.5 turn premium. $10-25M EBITDA: 0.5-1 turn premium. $25-50M EBITDA: 1-1.5 turn premium. $50M+ EBITDA: 1.5-3 turn premium and access to strategic synergy multiples. The size premium reflects buyer pool depth, capital structure economics, and the cost-amortization of fund-level diligence and management overhead.

Factor 3: recurring contracted revenue percentage. 30% recurring or below: 0.5-1 turn discount versus baseline. 30-50% recurring: at-baseline pricing. 50-70% recurring: 0.5 turn premium. 70%+ recurring: 1-1.5 turn premium and access to the premium buyer pool. Recurring revenue must be contracted (multi-year LTAs with volume commitments and pricing escalators), sole-source designations on OEM bills of materials, or aftermarket service parts — not just ‘loyal repeat customers.’ The distinction is real and sophisticated buyers test it during diligence.

Factor 4: customer concentration discount. Top customer under 15% of revenue: no discount. 15-25%: acknowledged but rarely repriced. 25-40%: 0.5-1.5 turn discount and earnout conversations. 40-50%: most LMM PE platforms require an earnout structure tied to customer retention (1-1.5 turns of multiple effectively shifted to contingent consideration). 50%+: deal compresses 1.5-3 turns and structure becomes heavily contingent. The concentration discount is one of the most-fought-over adjusters in manufacturing M&A and the one most owners try to obscure (which always backfires at QoE).

Factor 5: growth premium. Below 5% organic growth: 0.5-1 turn discount versus baseline. 5-10% organic growth: at-baseline. 10-20% organic growth: 0.5 turn premium. 20%+ sustained organic growth: 1-1.5 turn premium. Growth must be organic (not acquired) and sustained (3-year track record, not one-time spike). Buyers heavily discount one-time growth from a single big customer win or a temporary commodity price tailwind. Sustained growth signals defensible market position, healthy customer relationships, and operational scalability — all of which justify multiple expansion.

Industry baseline by size band: 2026 manufacturing data

The industry baseline for manufacturing EBITDA multiples in 2026 follows clear size bands, triangulated from GF Data DealStats, BVR DealStats, Pitchbook industrials, and public 10-K disclosures from serial industrial acquirers. The 2024-2026 vintage data shows aerospace and medical device sub-verticals near or above 2021 peaks; commodity contract manufacturing and automotive Tier-2 remain compressed 0.5-1 turn from 2021. Below are the 2026 baselines by size band, before sub-vertical and 4-factor adjusters.

Sub-$2M EBITDA: 4-6x EBITDA baseline. Buyer pool: search funders ($1-3M EBITDA target), independent sponsors, small strategic consolidators, occasional PE add-on programs willing to bolt on tuck-in targets. Owner-operated machine shops sub-$1.5M EBITDA typically shift to SDE multiples (3-5x SDE). Multiple compression below 4x EBITDA happens for owner-dependent businesses without second-tier management or recurring contracted revenue. Quality benchmarks at this size: 24+ months of monthly closes, 36 months of CPA-prepared financials, documented add-backs with supporting receipts.

$2-5M EBITDA: 5-7x EBITDA baseline. Buyer pool: full LMM PE platform competition begins. Active buyers at this size include Trive Capital (multiple platforms), Mason Wells (industrial CM), Wynnchurch Capital (metal fabrication), Argosy Capital (specialty CM), GenNx360 Capital Partners (precision machining), Sterling Group (manufacturing), plus search funders pursuing the upper end. Multiples cluster at 5.5-6.5x for general CM, 6-7x for precision machining with ISO 9001+, 7-8.5x for AS9100-certified aerospace work, 8-10x for ISO 13485 medical device CM.

$5-10M EBITDA: 6-7.5x EBITDA baseline. Buyer pool: heart of LMM PE competition with 15-25 active platforms across sub-verticals. Active buyers include all $2-5M buyers plus Audax Industrial Services, Industrial Growth Partners (IGP), Cortec Group, GTCR Industrials add-on programs, Genstar Capital industrial investments. Multiple expansion drivers at this size: institutional-grade financial reporting (CPA-reviewed financials, monthly closes within 10 days, 3-year forward forecasting capability), real second-tier management (plant manager, controller, sales lead, ops manager), modern manufacturing ERP (Epicor, Plex, IQMS, Global Shop, ProShop).

$10-25M EBITDA: 6.5-8.5x EBITDA baseline. Buyer pool: full LMM PE competition plus upper LMM PE entry. Active buyers include all of the above plus Carlyle Industrials add-on programs, Bain Capital Industrials, occasional Onex industrial deals. Strategic consolidators (NYSE: APi Group [APG], NASDAQ: HEICO [HEI], NYSE: Atkore [ATKR], NYSE: Roper Technologies [ROP] subsidiaries) actively pursue tuck-ins at this size and often pay premium to LMM PE multiples. Multiple expansion drivers: end-market diversification, geographic footprint, certification depth, growth trajectory above 8-10% organic.

$25-50M EBITDA: 7-9.5x EBITDA baseline. Buyer pool: upper LMM PE and lower middle-market PE compete. KKR Industrials (and Global Infrastructure Partners pre-BlackRock), Carlyle Industrials platforms, Bain Capital industrials, Apollo Global Management industrials, Onex industrial investments, plus continued LMM platform activity. Strategic consolidators pay premium for the right strategic fit (NASDAQ: HEICO [HEI] paying 8-12x for aerospace aftermarket; TransDigm paying 10-15x for proprietary aerospace; NYSE: Roper Technologies [ROP] paying 12-16x for niche industrial software/equipment). The strategic premium at this size can be 1.5-3 turns above the LMM PE baseline.

$50M+ EBITDA: 8-12x EBITDA baseline. Buyer pool: true middle-market PE plus full strategic consolidator competition plus public market exit options (IPO, SPAC). Multiples cluster at 8-10x for general industrial platforms, 10-13x for aerospace AS9100/NADCAP platforms, 11-14x for medical device CM platforms. Strategic synergy multiples can push 13-16x for niche-monopoly positions. Sponsor-to-sponsor recapitalization deals (PE buying from PE) typically clear at the lower end of the range; strategic and IPO/SPAC alternatives push to the higher end.

Why multiples compress for sub-$2M EBITDA: the capital structure floor

Multiples compress meaningfully below $2M EBITDA because the buyer pool collapses to capital structures that mathematically can’t support higher multiples. LMM PE platforms typically have minimum check sizes of $5-10M of equity capital deployed per platform. Backing into the EBITDA threshold that supports those checks at typical LMM multiples (5-7x) and capital structures (40-60% leverage) produces a $2-3M EBITDA floor. Below the floor, the math doesn’t work: management fees don’t justify the diligence cost, board oversight doesn’t scale, and the platform thesis (3-5 year value creation) doesn’t produce fund-level returns on a sub-$15M TEV deal.

What lives below the $2M EBITDA floor. Search funders raising $400K-$700K of search capital backed by 10-20 individual investors actively target $1-3M EBITDA manufacturing businesses. Multiples: 4-5.5x EBITDA. Independent sponsors operating deal-by-deal target $500K-$5M EBITDA. Multiples: 3.5-5.5x EBITDA. SBA-financed individuals dominate sub-$1M SDE machine shop space. Multiples: 3-5x SDE (effectively 2.5-4x EBITDA after correcting for owner compensation). Each of these buyer types has a capital structure that mathematically forces lower multiples than LMM PE platforms can pay.

Why this matters for owners within $500K of the threshold. On a $1.7M EBITDA precision machining business, the realistic LMM PE buyer pool might be 4-8 firms willing to look. On a $3.2M EBITDA precision machining business, that pool expands to 20-30 firms. The expansion in buyer competition alone supports 0.5-1 turn of multiple expansion. Owners within $500K-$1M of the next size threshold often benefit from waiting 12-24 months to grow into the wider buyer pool — the multiple expansion plus the additional EBITDA growth typically produces 30-60% more after-tax proceeds.

Worked example: the difference $1.5M of EBITDA growth makes. $1.7M EBITDA precision machining at 5.5x = $9.4M TEV. $3.2M EBITDA precision machining at 7x (size premium plus full LMM PE competition) = $22.4M TEV. The 88% revenue growth produces 138% TEV growth. Even if the growth requires 2 years of intentional preparation (customer diversification, certification work, ERP discipline), the math typically supports waiting. The owners who exit at sub-$2M EBITDA are usually the ones forced by external circumstances (health, conflict, liquidity crisis), not the ones who optimized timing.

Why multiples expand for $5M+ EBITDA: the buyer pool and operational scale effects

Multiples expand meaningfully at $5M+ EBITDA because three reinforcing dynamics activate. First, the LMM PE buyer pool expands from 8-12 firms (sub-$3M EBITDA) to 20-30 firms (full LMM PE competition). Second, public strategic consolidators (NYSE: APi Group [APG], NASDAQ: HEICO [HEI], NYSE: Atkore [ATKR], NYSE: Roper Technologies [ROP]) engage actively at this size, often paying 1-2 turn premiums above LMM PE for the right strategic fit. Third, businesses at this scale typically have institutional-grade financial reporting, real second-tier management, modern ERP discipline, and operational benchmarks that command premium pricing.

What changes operationally at $5M+ EBITDA. Most $5M+ EBITDA manufacturing businesses run on real ERP (Epicor, Plex, IQMS, Global Shop, ProShop) with monthly closes within 10 days, CPA-reviewed (or audited) financials, real plant manager and controller, dedicated quality manager, sales VP or director, separate ops and finance leadership. The owner’s role has shifted from operating brain to strategic leadership. Customer relationships are documented in CRM. Quality systems are formalized (ISO 9001 minimum, often ISO 13485 or AS9100). Scorecards are tracked weekly. The business runs without the owner; the owner is no longer a single point of failure.

Why public consolidators pay premiums at this size. Public consolidators have lower cost of capital than PE platforms (public equity market multiple vs PE fund hurdle), they have proven integration playbooks (HEICO has acquired 100+ businesses, APi Group has acquired 50+, Roper has acquired 100+), they realize real synergy economics (revenue cross-sell, cost takeout, geographic coverage, capability expansion), and they have ongoing acquisition programs that depend on continued deal flow. The 1-2 turn premium is justified by post-acquisition EBITDA expansion typically targeted at 15-30% within 24-36 months of close.

Strategic synergy multiples at the high end. Recent disclosed deals from public consolidators show the upper range of the strategic premium. NASDAQ: HEICO (HEI) recent acquisition multiples in 10-K filings: 8-12x EBITDA for aerospace aftermarket businesses. TransDigm: 10-15x EBITDA for proprietary aerospace component businesses. NYSE: Roper Technologies (ROP): 12-16x EBITDA for niche industrial software/equipment. These multiples are not available to all sellers — they require genuine strategic fit, certification depth, and competitive position. But for the businesses that qualify, the gap to LMM PE pricing is 2-4 turns.

Sub-vertical adjusters: applying the framework across manufacturing types

Sub-vertical adjusters sit on top of the size baseline and the four 4-factor adjusters. Aerospace AS9100/NADCAP and medical device ISO 13485/FDA each command structural premiums above the general manufacturing baseline. Plastics injection molding and metal stamping/fabrication trade at modest discounts due to capital intensity. Electronic contract manufacturing (ECM/EMS) trades at general CM baselines but with thin gross margins compressing the absolute dollar value.

Aerospace AS9100/NADCAP: +1-2 turns above baseline. AS9100D quality system and NADCAP accreditation for special processes (NDT, heat treat, chemical processing, welding, magnetic particle inspection) command premiums driven by certification scarcity, OEM qualification cycles of 18-36 months locking incumbents in, and 60-80% recurring contracted revenue under multi-year LTAs. Active buyers: GenNx360 Capital Partners, Audax Industrial Services, GTCR Industrials, Arlington Capital Partners, Greenbriar Equity Group, Cortec Group, Liberty Hall Capital Partners. Strategic consolidators: NASDAQ: HEICO (HEI), TransDigm, NYSE: Roper Technologies (ROP) subsidiaries. ITAR-restricted defense work adds 0.5-1 turn premium for U.S.-controlled buyers.

Medical device contract manufacturers (ISO 13485 / FDA registered): +2-4 turns above baseline. FDA 21 CFR Part 820 quality system, ISO 13485 certification, 2-5 year regulatory submission and qualification cycles, 70%+ recurring contracted revenue, demographic-aging tailwind. Buyers: medical-focused PE (Linden Capital Partners, Riverside Healthcare Capital Group, GTCR Healthcare, Bain Capital Healthcare, NewSpring Capital Healthcare, Avista Capital, Frazier Healthcare Partners), strategic acquirers (Integer Holdings [NYSE: ITGR], Heraeus Medical Components, Phillips-Medisize, Tecomet, Cretex Medical). Class III implantable device CMs trade at the very top of the range due to regulatory moat depth.

Plastics injection molding: -0.5 to -1 turn versus baseline. High capex intensity (6-9% of revenue), recurring contracted production parts on OEM bills of materials, customer concentration often higher than other CM sub-verticals (Tier-2 automotive, industrial equipment OEMs). Active buyers: Trive Capital (multiple plastics platforms), Mason Wells, Wynnchurch Capital, Argosy Capital. The capex burden is the primary multiple-compressor; owners who maintain a clean 5-year capex history with documented mold and equipment replacement plans protect against further compression.

Metal stamping and fabrication: at-baseline to -0.5 turn. 5-8% maintenance capex intensity, recurring contracted production parts in industrial equipment, automotive Tier-2, agricultural equipment, construction equipment end-markets. Active buyers: Wynnchurch Capital, Mason Wells, Argosy Capital, Sterling Group. End-market mix matters significantly: 60% aerospace and medical exposure trades 0.5-1 turn above 100% automotive Tier-2 exposure due to recession sensitivity differential.

Electronic contract manufacturing (ECM/EMS): at-baseline. Light capex (3-5% of revenue) but heavy inventory and component-cost pass-through, gross margins compressed (12-22%) by component cost dynamics, customer concentration often high. IPC Class 3 (high-reliability) certifications and medical/aerospace-qualified EMS designations support premium positioning. Active buyers: TPG Capital industrial investments, Genstar Capital, Trive Capital, Bain Capital industrials. Strategic consolidators include Sanmina, Jabil, Benchmark Electronics, Plexus.

Capital intensity normalization: the gap between reported and cash EBITDA

Capital intensity normalization is mandatory in manufacturing valuation but consistently overlooked in self-estimates. Reported EBITDA — which adds back depreciation — ignores the equipment replacement obligation that defines manufacturing. Sophisticated buyers underwrite to cash EBITDA = reported EBITDA − 3-year average maintenance capex. The gap is typically 15-30% of reported EBITDA, meaningful enough to shift multiple decisions by 1-2 turns within the framework above.

Maintenance capex benchmarks by sub-vertical. General machine shops: 3-5% of revenue. Precision machining: 5-7% of revenue. Plastic injection molding: 6-9% of revenue (heavy press and tooling). Metal stamping and forming: 5-8% of revenue. Aerospace machining (AS9100): 5-8% of revenue plus 2-4% in tooling-specific spend. Medical device CMs: 6-10% of revenue with cleanroom infrastructure. Electronic contract manufacturing: 3-5% of revenue. These benchmarks come from AMT (Association for Manufacturing Technology) economic surveys, NTMA (National Tooling and Machining Association) member data, and PMA (Precision Metalforming Association) industry reports.

How sophisticated QoE providers normalize. QoE providers with manufacturing depth (Plante Moran Manufacturing & Distribution practice, BDO, Crowe, RSM Manufacturing & Distribution, Wipfli, Eide Bailly, Cohn Reznick) request 5-year capex history with line-item detail. They categorize each spend as maintenance versus growth. They benchmark the maintenance percentage against sub-vertical norms. They build a 5-year forward capex forecast tied to specific equipment age and replacement schedule. They calculate cash EBITDA = reported EBITDA − normalized maintenance capex, and they price closer to cash EBITDA than reported EBITDA when working within multiple ranges.

The deferred capex trap. If reported EBITDA is artificially elevated because the owner has deferred 3-5 years of equipment refresh capex, sophisticated QoE will catch it. The fix isn’t to keep deferring; it’s to acknowledge the capex liability up front and price the deal accordingly. A precision shop with 15-year-old CNC equipment may need $2-4M of replacement capex in the next 3-5 years; that future obligation reduces the realistic multiple by 0.5-1 turn versus a comparable shop with a clean 5-year capex history. Owners who walk into diligence with a clean fixed-asset register, equipment-replacement plan, and 3-year capex history protect their multiple.

Working through the framework: a complete valuation example

Let’s walk through the complete 4-factor framework on a real example. Setup: $14M revenue precision machining business, AS9100 certified, $2.05M normalized 3-year average EBITDA, $880K average maintenance capex (6.3% of revenue), top customer 32% of revenue under a 3-year LTA expiring in 14 months, top 3 customers 58%, 65% of revenue under multi-year LTAs, 8% organic growth over the past 3 years, real plant manager and controller in place, ERP on Epicor.

Step 1: industry baseline. Sub-vertical: AS9100-certified precision machining. Size band: $2.05M EBITDA, sub-$2M-to-$2-5M boundary. Aerospace AS9100/NADCAP +1-2 turns above general baseline; precision machining baseline 6-7x at $2-5M EBITDA size band. Aerospace baseline: 7-9x. Working starting baseline: 7-8.5x EBITDA.

Step 2: size adjuster. $2.05M EBITDA is at the low end of the $2-5M band, with limited LMM PE platform competition. Apply 0.5 turn discount versus the higher end of the band. Adjusted: 6.5-8x.

Step 3: recurring revenue adjuster. 65% of revenue under multi-year LTAs. Above the 50-70% range but below the 70%+ premium tier. Adjuster: +0.5 turn premium. Adjusted: 7-8.5x.

Step 4: customer concentration adjuster. Top customer 32% (in the 25-40% band): -0.75 to -1.25 turn discount. Top 3 customers 58% (compounds the concentration risk): additional -0.25 to -0.5 turn discount. Combined concentration adjuster: -1 to -1.75 turns. Adjusted: 5.25-7.5x. The wide range reflects the binary nature of how individual buyers price the LTA expiring in 14 months: a buyer who underwrites it as renewable pays toward the top; a buyer who reflexively discounts pays toward the bottom.

Step 5: growth premium adjuster. 8% organic growth over 3 years: in the 5-10% range, at-baseline pricing. Adjuster: 0 (no premium or discount). Final adjusted multiple range: 5.25-7.5x EBITDA.

Step 6: capital intensity normalization. Reported EBITDA $2.05M minus $880K maintenance capex = $1.17M cash EBITDA. Disciplined buyers anchor toward cash EBITDA when deciding within the multiple range. Apply 5.25-7.5x to $2.05M EBITDA: TEV range $10.8M-$15.4M. The buyer who anchors heavily on cash EBITDA might apply 8-10x to $1.17M = $9.4M-$11.7M of TEV equivalent — the implied multiple on reported EBITDA is 4.6-5.7x. The seller who walks in unprepared sees this as a re-trade at LOI; the seller who’s built the cash EBITDA and capex story up front sees it as a defensible negotiation.

Step 7: improving the multiple through preparation. Renewing the expiring LTA before going to market eliminates the ‘contract expiry’ concern and tightens the range to 6-7.5x. Reducing top customer to 22% through 18 months of customer diversification eliminates the concentration discount and pushes the range to 7-8.5x. The combined preparation moves shift the multiple from 5.25-7.5x to 7-8.5x — a gain of 1.5-2 turns. On $2.05M EBITDA, that’s $3-4M of additional TEV. The 18 months of preparation is real money.

Common framework mistakes (and how disciplined buyers exploit them)

Mistake 1: anchoring on baseline without applying adjusters. Owners read ‘$5-10M EBITDA precision machining = 7x baseline’ and apply 7x to their $4M EBITDA business with 38% customer concentration. The actual range after adjusters is closer to 5.5-6.5x, a 0.5-1.5 turn gap from the assumed 7x. The conversation with sophisticated buyers consistently produces lower numbers than the seller expected, leading to LOI re-trades and broken deals.

Mistake 2: hiding customer concentration in the CIM. Many owners produce CIMs that obscure top-customer concentration, hoping buyers won’t catch it before LOI. Sophisticated buyers (Audax Industrial, Industrial Growth Partners, Sterling Group, GenNx360, Wynnchurch, Trive Capital) request 36-60 months of customer-by-customer revenue history within the first week of LOI diligence. They find the concentration. They re-trade aggressively. The LOI re-trade kills more manufacturing deals than any other single factor. Honest CIMs with the mitigation story (LTAs, sole-source designations, multi-program presence) anchor better.

Mistake 3: confusing recurring with repeat revenue. Owners self-estimate 80% recurring revenue when the actual figure under contract is 35%. The other 45% is ‘repeat’ — loyal customers reordering regularly without volume commitments. Buyers separate the two during diligence. Recurring contracted revenue at 35% with another 45% repeat-but-not-contracted revenue produces a different multiple than 80% recurring contracted. The 0.5-1 turn difference in the framework adjuster is real.

Mistake 4: ignoring maintenance capex in the multiple calculation. Self-estimating $2M EBITDA precision shop at 7.5x produces $15M of TEV. But sophisticated buyers anchor on $1.2M cash EBITDA after $800K of maintenance capex, applying 6-7x to that — producing $7.2-8.4M of TEV. The gap is dramatic. Bring a clean 5-year capex history and equipment-replacement plan to QoE and you protect against the worst of the discount; ignore it and the buyer’s analysis dominates yours.

Mistake 5: anchoring on Pitchbook headlines without size and sub-vertical adjustment. ‘Industrials traded at 8.4x in Q4’ describes the median across $25M+ EBITDA platform deals with strong recurring revenue and clean concentration profiles. It is not the multiple for a $2M EBITDA machine shop with 38% concentration. The most expensive owner mistake in manufacturing valuation is reading the right number for the wrong business. Triangulate from the size-band-specific data in GF Data DealStats and BVR DealStats, not from aggregate trade press headlines.

Mistake 6: pricing on TTM EBITDA in late-cycle conditions. If TTM EBITDA is peak-cycle (one-time customer rush, temporary commodity price spike, deferred capex inflating reported earnings), sophisticated buyers will normalize down to mid-cycle EBITDA. Cycle-aware QoE providers will use 3-5 year average normalized EBITDA, not TTM. Owners going to market in late-cycle conditions need to be especially careful about pricing on TTM EBITDA — a cycle-trough comparable can re-price a deal by 0.5-1 turn.

How recent strategic deals validate the framework

Public 10-K disclosures from serial industrial acquirers provide individual-deal data points that validate the framework above. NASDAQ: HEICO (HEI), TransDigm Group, NYSE: APi Group (APG), NYSE: Atkore (ATKR), NYSE: Roper Technologies (ROP), NYSE: Watsco (WSO), NYSE: Comfort Systems USA (FIX) all disclose acquisition multiples, EBITDA contributions, and structural details for material acquisitions. The disclosed multiples cluster at 1-2 turns above the LMM PE baseline for the right strategic fit, and at 3-5 turns above for niche-monopoly positions.

NASDAQ: HEICO (HEI) — aerospace aftermarket consolidator. HEICO has built a $20B+ market cap by acquiring 100+ specialty aerospace component businesses since 1990. Recent disclosed deal multiples in 10-K filings have ranged from 7-12x EBITDA depending on certification depth, customer relationships, and FAA Parts Manufacturer Approval (PMA) library size. HEICO’s edge: long-cycle aftermarket revenue from installed-base aerospace fleets that compounds over decades. The HEICO model demonstrates that for aerospace aftermarket businesses with the right certification and customer profile, the multiple can be 1-2 turns above the AS9100 baseline.

TransDigm Group — proprietary aerospace components. TransDigm has built a $90B+ market cap by acquiring proprietary, sole-source aerospace component manufacturers. Public disclosures and trade press indicate acquisition multiples in the 10-15x EBITDA range, reflecting 70%+ recurring aftermarket revenue, FAA-certified proprietary positions, and pricing power from sole-source designations. TransDigm-quality businesses are rare but command the highest multiples in aerospace M&A — 3-5 turns above the AS9100 LMM baseline.

NYSE: Roper Technologies (ROP) — niche industrial and software/equipment. Roper has built a $50B+ market cap through 100+ acquisitions of niche industrial software, measurement, and analytical equipment businesses. Roper’s acquisition multiples disclosed in 10-K filings have averaged 12-16x EBITDA — the highest in the industrials consolidator space. Drivers: niche-monopoly thesis (products with no real substitutes), 80%+ recurring revenue characteristics in target software businesses, decentralized operating model. Roper-style deals are at the very top of the industrials multiple range.

NYSE: APi Group (APG) and NYSE: Atkore (ATKR) — specialty contractor and electrical consolidation. APi Group ($14B+ market cap) consolidates specialty contractor businesses including manufacturing components for fire protection equipment, specialty metals, and HVAC. Public disclosures indicate acquisition multiples in the 7-10x EBITDA range. Atkore (electrical raceway and conduit) consolidates electrical product manufacturing and distribution, with disclosed acquisition multiples in the 7-10x range as well. NYSE: Comfort Systems USA (FIX) acquires mechanical contractors with embedded manufacturing capability at similar multiples. These deals validate the LMM-plus-strategic-premium framework: 1-2 turns above LMM PE baseline for clear strategic fit.

The path from baseline multiple to actual deal price

The multiple is the headline; the deal price is what actually clears. From baseline EBITDA multiple to net after-tax proceeds, manufacturing deals pass through a layered set of adjustments: working capital peg negotiation, debt at close, transaction costs, asset versus stock structure, federal and state taxes, depreciation recapture on equipment, capital gains on goodwill, and (often) seller financing or earnout exposure. A 7x EBITDA multiple on $4M EBITDA produces $28M of TEV; the seller’s wire at close is often $18-22M of cash with another $3-5M in seller note over 7-10 years and $0-3M in earnout.

Working capital peg as the single biggest below-the-line variable. Manufacturing businesses carry significant working capital: typically 20-30% of revenue depending on sub-vertical. The peg is calculated as a trailing 12-24 month average. Manufacturing businesses with seasonal patterns (HVAC component CMs, agricultural CMs, pool and spa equipment CMs) need especially careful peg construction. Without seasonal adjustment, the seller can give back $500K-$1.5M at close on a $20M deal.

Asset versus stock structure mechanics. Manufacturing deals below ~$15M TEV are typically structured as asset sales (buyer prefers for liability protection and depreciation step-up). Asset allocation across categories (Form 8594) drives the seller’s tax bill: equipment and inventory subject to ordinary income recapture (up to 37% federal + state); goodwill subject to long-term capital gains (15-20% federal + state); non-compete is ordinary income to seller, deductible to buyer; consulting agreement is ordinary income spread over period. Stock sales above ~$15-20M TEV produce pure long-term capital gains treatment, typically 10-20% better after-tax than equivalent asset sales.

Seller financing and earnout exposure. Manufacturing deals at the smaller end (sub-$10M TEV) often require 15-30% seller financing (10-year amortization, 6-9% interest, subordinated to bank debt). Larger deals more rarely require seller financing but may include earnout structures tied to customer retention (typical for deals with 30%+ customer concentration), revenue or gross margin growth (typical for high-growth businesses), or post-close synergy realization (typical for strategic acquirers). Realistic earnout collection rates: 60-80% on revenue/margin earnouts, 70-85% on customer retention earnouts in manufacturing.

Sub-vertical multiple shifts 2019-2026: aerospace, medical, automotive, plastics

Manufacturing multiples have shifted meaningfully across the 2019-2026 cycle, with each sub-vertical telling a distinct story. Aerospace AS9100/NADCAP multiples expanded from 6-8x in 2020 (COVID-driven commercial production cuts) to 7-10x in 2026 as Boeing 737 MAX recovery, Airbus A320 family rate increases, and military/defense spending supported sustained recovery. Medical device ISO 13485/FDA CMs have been the most consistently expanding sub-vertical: 7-10x in 2019, 8-12x in 2026. Automotive Tier-2 has been the most cyclical: 5-7x in 2019, compressed to 4-6x in late 2022 during EV transition uncertainty, partial recovery to 4.5-6.5x in 2026.

Aerospace expansion drivers 2022-2026. Boeing 737 MAX production rate restoration following the 2019-2020 grounding and 2022-2024 production stabilization. Airbus A320 family rate increases announced in 2023-2024 (target 75/month). Defense spending increases driven by geopolitical events (Ukraine, Indo-Pacific posture). Sustained Tier-1 OEM consolidation pressure on supply base, supporting consolidator multiples (NASDAQ: HEICO [HEI] particularly active). Commercial aviation aftermarket recovery as global passenger volumes returned to pre-COVID levels in 2024-2025.

Medical device CM expansion drivers. Demographic-aging tailwind (U.S. population over 65 growing 3-4% annually). Increasing OEM outsourcing trend as device companies focus capital on R&D and commercialization rather than manufacturing infrastructure. Active PE consolidation by sector specialists (Linden Capital Partners has built multiple platforms; Riverside Healthcare, GTCR Healthcare, Bain Healthcare equally active). Strategic consolidation by Integer Holdings (NYSE: ITGR), Phillips-Medisize, Tecomet, Cretex Medical. Class III implantable device CMs trade at the very top of the range due to deepest regulatory moat.

Automotive Tier-2 compression and gradual recovery. EV transition uncertainty compressed Tier-2 automotive CM multiples in 2021-2023 as buyers worried about ICE-vehicle component obsolescence. Multiples compressed 1-2 turns versus historical baselines. 2024-2026 has seen partial recovery as the EV transition timeline extends, ICE production stabilizes longer than feared, and Tier-2 suppliers with both ICE and EV exposure trade closer to historical multiples. Tier-2 auto CMs without EV exposure remain compressed; those with established EV programs trade at or above historical multiples.

Plastics and stamping multiple trajectories. Plastic injection molding multiples expanded from 3.5-5x in 2019 to 4.5-6.5x in 2026, driven by reshoring narrative, automotive aluminum-to-plastic substitution, and active PE consolidation by Trive Capital and Mason Wells. Metal stamping and fabrication multiples expanded from 4-5.5x in 2019 to 4.5-6.5x in 2026, with end-market mix driving variance: aerospace and medical exposure trades 0.5-1 turn higher than automotive Tier-2 or construction equipment exposure.

How to use the framework in your sale planning timeline

The 4-factor framework drives planning decisions, not just final pricing. If you can shift two adjusters (e.g., raise recurring revenue from 40% to 65% and reduce concentration from 38% to 22%) over 18 months, you can plausibly add 1.5-2.5 turns of multiple. On $4M EBITDA, that’s $6-10M of additional TEV. The investment in customer diversification, contract conversion, certification achievement, and ERP discipline is meaningful but the return is real.

Months 24-18: financial cleanup and ERP discipline. Move to monthly closes within 15 days. Reconcile bank, AR, AP, and inventory accounts to the books monthly. Get CPA-prepared (not just bookkeeper-prepared) annual financial statements; if budget allows, reviewed financials ($15-30K/year for manufacturing). Migrate to or stabilize a real manufacturing ERP (Epicor, Plex, IQMS, Global Shop, ProShop). The cost of ERP migration is real ($75-300K) but the buyer-perceived value is significantly higher — messy financials in spreadsheets compress multiples by 0.5-1 turn within the framework.

Months 18-12: customer diversification and LTA conversion. Build a 12-month customer acquisition plan to add 5-15 new accounts. For top 3-5 customers, negotiate or extend long-term agreements (3-5 year terms with annual pricing escalators tied to PPI or CPI manufacturing). Migrate purchase-order-only customers to LTAs where possible. The combination of new account acquisition and contract conversion can shift recurring revenue from 35% to 65% over 12-18 months, plus reduce top-customer concentration meaningfully — worth 1-2.5 turns of multiple in the framework.

Months 12-6: certifications and operational documentation. If you don’t have ISO 9001, get it. If you serve aerospace customers without AS9100, the certification process takes 9-15 months and is worth 1-2 turns of multiple. Same for ISO 13485 (medical) and NADCAP for special processes. Document SOPs for the top 20-30 operational processes. Build a quality dashboard with on-time delivery, first-pass yield, customer scorecard ratings.

Months 6-0: diligence package preparation. 36 months of monthly P&Ls, balance sheets, cash flow. 36-60 months of customer-by-customer revenue history. Documented add-backs with line-item supporting receipts. 24-month working capital trend with category breakdowns. Fixed-asset register with model numbers, acquisition dates, accumulated depreciation, remaining useful life, and 5-year replacement plan. All customer LTAs, supplier agreements, equipment leases, real estate leases, employment agreements, IP/patent documentation. Quality certifications and customer scorecards. The cleaner the package, the smoother QoE runs.

Validation and going to market. Before going to market, validate your framework-derived multiple range against actual buyer feedback. A 30-minute conversation with a buy-side partner who knows the manufacturing buyer pool produces a more useful range than a $15K credentialed appraisal. The conversation produces: realistic multiple range tied to your specific profile, identification of the 3-5 specific buyer archetypes who would actually look at your business, and structural read on which deal mechanics typically apply for businesses like yours.

Conclusion

The right manufacturing EBITDA multiple is industry baseline plus 4 structural adjusters — size, recurring revenue, concentration, growth. Baseline is set by sub-vertical (machine shop versus CM versus precision versus aerospace versus medical device) and size band (sub-$2M EBITDA = 4-6x, $2-5M = 5-7x, $5-10M = 6-7.5x, $10-25M = 6.5-8.5x, $25-50M = 7-9.5x, $50M+ = 8-12x). Adjusters move you 0.25-1.5 turns each: size premium/discount, recurring contracted revenue percentage, customer concentration discount, growth premium. Capital intensity normalization (cash EBITDA = reported − 3-year average maintenance capex) shapes how disciplined buyers price within the multiple range. Multiples compress meaningfully sub-$2M EBITDA (capital structure floor) and expand meaningfully at $5M+ (full LMM PE competition plus public consolidator engagement). The owners who realize the highest manufacturing multiples are the ones who apply the framework honestly, identify the 1-2 highest-leverage adjusters, invest 18-24 months in shifting them, and validate against actual buyer feedback before going to market. And if you want to talk to someone who knows the 38 manufacturing-focused buyers in the LMM universe personally instead of running an auction, we’re a buy-side partner — the buyers pay us, not you, no contract required.

Frequently Asked Questions

What EBITDA multiple does a manufacturing business sell for in 2026?

Manufacturing TEV/EBITDA multiples in 2026 follow size bands: sub-$2M EBITDA = 4-6x, $2-5M = 5-7x, $5-10M = 6-7.5x, $10-25M = 6.5-8.5x, $25-50M = 7-9.5x, $50M+ = 8-12x (per GF Data DealStats, BVR DealStats, Pitchbook industrials). Sub-vertical adjusters: aerospace AS9100/NADCAP +1-2 turns; medical device ISO 13485/FDA +2-4 turns; commodity CM at baseline; machine shop -1-2 turns or shift to SDE multiple. Apply the 4-factor framework to land on a defensible range.

What is the size premium / discount for manufacturing EBITDA multiples?

Sub-$2M EBITDA: 0.5-1 turn discount versus baseline (capital structure floor — LMM PE platforms can’t deploy $5-10M equity into sub-$2M EBITDA businesses at 5-7x). $2-5M EBITDA: at-baseline. $5-10M: 0.25-0.5 turn premium. $10-25M: 0.5-1 turn premium (full LMM PE competition). $25-50M: 1-1.5 turn premium. $50M+: 1.5-3 turn premium and access to strategic synergy multiples from public consolidators.

How does recurring contracted revenue percentage affect manufacturing multiples?

30% recurring or below: 0.5-1 turn discount. 30-50%: at-baseline. 50-70%: +0.5 turn premium. 70%+: +1-1.5 turn premium and access to premium buyer pool. Recurring must be contracted (multi-year LTAs with volume commitments and pricing escalators), sole-source designations on OEM bills of materials, or aftermarket service parts. Loyal repeat customers without contracted volumes do NOT count as recurring.

What customer concentration is acceptable for manufacturing M&A?

Under 15% concentration: no discount. 15-25%: acknowledged but rarely repriced. 25-40%: 0.5-1.5 turn discount and earnout conversations. 40-50%: most LMM PE platforms require an earnout structure tied to customer retention (1-1.5 turns shifted to contingent consideration). 50%+: 1.5-3 turn compression and heavily contingent structure. Mitigations: 3-5 year LTAs with volume commitments, sole-source designations, multi-program presence at the same OEM, AS9100/ISO 13485 certifications creating switching costs.

What growth premium is available for high-growth manufacturers?

Below 5% organic growth: 0.5-1 turn discount versus baseline. 5-10% organic growth: at-baseline. 10-20% organic: +0.5 turn premium. 20%+ sustained organic growth: +1-1.5 turn premium. Growth must be organic (not acquired) and sustained (3-year track record). Buyers heavily discount one-time growth from a single big customer win or temporary commodity tailwind. Sustained growth signals defensible market position, healthy customer relationships, operational scalability.

Why do manufacturing multiples compress for sub-$2M EBITDA businesses?

Capital structure mathematics. LMM PE platforms have minimum check sizes of $5-10M equity per platform, which back into a $2-3M EBITDA threshold at typical multiples (5-7x) and capital structures (40-60% leverage). Below that floor, the buyer pool collapses to search funders ($1-3M EBITDA target), independent sponsors, SBA-financed individuals, and small strategic consolidators. Each of these buyer types has capital structure constraints that mathematically force lower multiples than LMM PE can pay. The structural break is real.

Why do multiples expand at $5M+ EBITDA?

Three reinforcing dynamics. First, LMM PE buyer pool expands from 8-12 firms to 20-30 firms (full competition). Second, public strategic consolidators (NYSE: APi Group, NASDAQ: HEICO, NYSE: Atkore, NYSE: Roper) engage actively at this size, often paying 1-2 turn premiums above LMM PE for the right strategic fit. Third, businesses at this scale typically have institutional-grade reporting, real second-tier management, modern ERP, and operational benchmarks that command premium pricing.

How do public strategic consolidator multiples compare to LMM PE?

Public consolidators typically pay 1-2 turns above the LMM PE multiple band when strategic fit is clear. NASDAQ: HEICO recent acquisition multiples: 7-12x EBITDA for aerospace aftermarket businesses. TransDigm: 10-15x for proprietary aerospace components. NYSE: Roper Technologies: 12-16x for niche industrial software/equipment. NYSE: APi Group, NYSE: Atkore, NYSE: Comfort Systems: 7-10x for specialty contractor/manufacturing acquisitions. The premium drivers: lower cost of capital, real synergy economics, proven integration playbooks across 50-100+ deals.

How does AS9100 certification affect aerospace manufacturer EBITDA multiples?

AS9100D certification typically supports +1-2 turns above the general manufacturing baseline for the same size band. NADCAP accreditation for special processes adds further premium. The reasoning: certification scarcity, OEM qualification cycles of 18-36 months locking incumbents in, 60-80% recurring contracted revenue from Tier-1 OEMs (Boeing, Airbus, Lockheed, Northrop, Spirit AeroSystems). ITAR-restricted defense work adds another 0.5-1 turn for U.S.-controlled buyers. Active aerospace LMM buyers: GenNx360, Audax Industrial, Arlington Capital, Greenbriar Equity, Cortec.

What is a typical EBITDA multiple for a medical device CM?

Medical device CMs operating under FDA 21 CFR Part 820 with ISO 13485 certification trade at +2-4 turns above the general manufacturing baseline. At $3-30M EBITDA, that’s typically 8-12x EBITDA. Class III implantable device CMs trade 10-13x. Drivers: 2-5 year regulatory submission cycles creating customer lock-in, 70%+ recurring contracted revenue, demographic-aging tailwind. Buyers: medical-focused PE (Linden Capital, Riverside Healthcare, GTCR Healthcare, Bain Healthcare) plus strategic acquirers (Integer Holdings [NYSE: ITGR], Phillips-Medisize, Tecomet, Cretex Medical).

How should I normalize for capital intensity when calculating my multiple?

Calculate 3-year average maintenance capex as a percentage of revenue (typical: 4-7% across manufacturing sub-verticals). Subtract from reported EBITDA to derive cash EBITDA. Sophisticated buyers anchor on cash EBITDA, not headline EBITDA, when deciding within the multiple range. A $2M reported EBITDA precision shop with $880K average maintenance capex underwrites at $1.12M cash EBITDA — meaningfully different at 6.5x = $7.3M versus $13M of TEV. Bring a clean fixed-asset register and 5-year replacement plan.

How does the framework apply to a sub-$1M owner-operated machine shop?

Sub-$1.5M EBITDA owner-operated machine shops shift from EBITDA multiples to SDE multiples. Baseline: 3-5x SDE for general machine shops. Apply the 4-factor adjusters: size compression (sub-$1M), recurring revenue (most sub-$1M shops have low recurring, 0.5 turn discount), concentration (30%+ common in this size, 0.5-1 turn discount), growth (rare to see strong growth at this size). Adjusted typical range: 2.5-4x SDE. Buyer pool: SBA-financed individuals dominate, search funders rare at this size.

How is CT Acquisitions different from a sell-side broker or M&A advisor?

We’re a buy-side partner, not a sell-side broker. Sell-side brokers represent you and charge you 8-12% of the deal (often $300K-$1M+) plus monthly retainers, run a 9-12 month auction process, and require 12-month exclusivity. We work directly with 76+ buyers — including 38 firms with explicit manufacturing mandates: Audax Industrial, Industrial Growth Partners, GenNx360, Trive, Mason Wells, Wynnchurch, Sterling Group, Argosy, Cortec, GTCR Industrials, family offices, and strategic consolidators (HEICO, APi Group, Atkore, Roper, Comfort Systems, Watsco, TransDigm) — who pay us when a deal closes. You pay nothing. No retainer, no exclusivity, no contract until a buyer is at the closing table. We move faster (60-180 days from intro to close) because we already know which of the 38 manufacturing-focused buyers in the network would actually look at your business rather than running an auction to find one.

Sources & References

All claims and figures in this analysis are sourced from the publicly available references below.

1. https://www.nam.org/
2. https://www.amtonline.org/
3. https://www.ntma.org/
4. https://www.bls.gov/iag/tgs/iag31-33.htm
5. https://www.bea.gov/data/gdp/gdp-industry
6. https://investors.heico.com/financials/sec-filings
7. https://investors.apigroupinc.com/financial-information/sec-filings
8. https://ropertech.gcs-web.com/financial-information/sec-filings